Navigation Links
Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
Date:4/24/2009

NANTONG CITY, China, April 24 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to report financial highlights from the unaudited financial results for the nine month period ended February 28, 2009.

Financial highlights include:

  • Sales revenue increased to US $2,715,702 for the nine months ended February 28, 2009, from US $1,170,677 in the corresponding period ended February 29, 2008.
  • Gross profit increased to US $1,815,491, representing 67% of sales revenue, for the nine months ended February 28, 2009, from US $435,666, representing 37% of revenue, in the corresponding period ended February 29, 2008.
  • Net profit of the Company's wholly owned operating subsidiary, Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., increased to US $851,324, representing 27% of sales revenue, for the nine months ended February 28, 2009, from - US $ 96,335 in the corresponding period ended February 29, 2008. However, the Company's overall net loss increased to US $1,622,692 for the nine months ended February 28, 2009, from US $444,672 for the nine months ended February 29, 2008, of which one of the main expenses affecting the results of operations was the stock-based compensation expense of US $1,944,750 reflecting the vesting of stock options granted by the Company having an exercise price of $1.80 per share.
  • Increase in sales volume and the improvement in gross profit percentage are both due to growth in sales of Cisatracurium Besylate, a skeletal muscle relaxant. Sales of this product increased to US $2,511,752 in the nine months ended February 28, 2009, from US $765,615 in the nine months ended February 29, 2008. At the same time, as volume has increased, cost of manufacturing Cisatracurium Besylate has decreased to 30% of its price for the nine months ended February 28, 2009, from 64% of its price for the nine months ended February 29, 2008.

"The significant increases in sales revenue as well as gross and net profit indicate not only the growing success of Sinobiopharma's products in the marketplace, but also the Company's improved performance in producing and distributing them more cost-effectively," said Mr. Lequn Huang, President and CEO of Sinobiopharma.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
2. Sinobiopharma, Inc. Appoints New Director of Marketing
3. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
4. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
5. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
6. Cepheid Reports 2009 First Quarter Results
7. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
8. Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008
9. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
10. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
11. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Cambridge Semantics ... that its Anzo Smart Data Lake® (Anzo SDL) product won ‘Best Text ... (SIIA) CODiE Awards. , Cambridge Semantics’ Anzo SDL uses Knowledge Graphs based ...
(Date:7/26/2017)... ... July 25, 2017 , ... The leading Regenerative Veterinary ... stem cell therapy has been used on more than 13,000 animals. VetStem ... potentially fatal injuries to tendons and ligaments. , In 2003 VetStem signed a ...
(Date:7/26/2017)... ... 26, 2017 , ... NLP Logix today announced a collaboration ... by Mayo Clinic and the experience in developing and deploying artificial intelligence solutions ... Microsoft Azure platform and will focus on assisting physicians to more accurately and ...
(Date:7/25/2017)... , ... July 25, 2017 , ... Fiberstar, Inc ... and beverage industry, offers Citri-Fi® 125. This natural citrus fiber is used to improve ... extend real tomato in sauces, condiments and spreads. Today, more than ever, consumers connect ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):